anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Post-pulmonary embolism syndrome is defined as exertional dyspnea or exercise intolerance after an acute pulmonary embolism treated with 3 months of anticoagulation. There are several etiologies including for example chronic thromboembolic pulmonary disease. A specialized work-up including echocardiography and pulmonary scintigraphy should be performed. A probability of chronic thromboembolic pulmonary hypertension is extrapolated so that invasive investigations can be performed if necessary. Identification of this pathology is decisive for specific management. Even without pulmonary hypertension, up to 20 % of patients after pulmonary embolism remain symptomatic with exertional dyspnea. Specific management for these patients needs to be defined.
PROBLEM TO BE SOLVED: To obtain the subject medicine useful for diseases related to the increase of bax or the decrease of bc1-2 by including a hepatocyte growth factor(HGF) as an active ingredient. SOLUTION: This agent for inducing the increase of bax and/or the increase of bc1-2 contains HGF as an active ingredient, and is useful for diseases related to the increase of the bax and/or the increase of the bc1-2, such as endothelial failures (diabetic endothelial failure) caused by hyperglycemia and ischemia. The medicine is prepared in various preparation forms (solutions, solid preparations, capsules, etc.,). For example, an injection is prepared by dissolving the HGF in a solvent such as sterilized water or a buffer solution, filtering the solution through a filter to sterilize the solution, and subsequently charging the sterilized solution into aseptic containers. The content of the HGF in the injection is usually preferably about 0.0002-0.2 W/V.%. The medicine is usually preferably administered at a dose of 0.05-500 mg as the HGF once or several times a day.
Branched-chain fatty acids (BCFAs) consist of a wide variety of fatty acids with alkyl branching of methyl group. The most common BCFAs are the types with one methyl group (mmBCFA) on the penultimate carbon (iBCFA) or the antepenultimate carbon (aiBCFA). Long-chain mmBCFAs are widely existing in animal fats, milks and are mostly derived from bacteria in the diet or animal digestive system. Recent studies show that BCFAs benefit human intestinal health and immune homeostasis, but the connection between their content, distribution in the human and their nutritional functions are not well established. In this paper, we reviewed BCFAs from various dietary sources focused on their molecular species. The BCFAs biosynthesis in bacteria, Caenorhabditis elegans, mammals and their distribution in human tissues are summarized. This paper also discusses the nutritional properties of BCFAs including influences on intestinal health, immunoregulatory effects, anti-carcinoma, and anti-obesity activities, by highlighting the most recent research progress.
BACKGROUND: Sleep deprivation (SD) can impair an individual's alertness, which is the basis of attention and the mechanism behind continuous information processing. However, research concerning the effects of total sleep deprivation (TSD) on alertness networks is inadequate. In this study, we investigate the cognitive neural mechanism of alertness processing after TSD.
METHODS: Twenty-four college students volunteered to participate in the study. The resting-state electroencephalogram (EEG) data were collected under two conditions (rested wakefulness [RW], and TSD). We employed isolated effective coherence (iCoh) analysis and functional independent component analysis (fICA) to explore the effects of TSD on participants' alertness network.
RESULTS: This study found the existence of two types of effective connectivity after TSD, as demonstrated by iCoh: from the left cuneus to the right middle frontal gyrus in the β3 and γ bands, and from the left angular gyrus to the left insula in the δ, θ, α, β1, β3, and γ bands. Furthermore, Pearson correlation analysis showed that increased effective connectivity between all the bands had a positive correlation with increases in the response time in the psychomotor vigilance task (PVT). Finally, fICA revealed that the neural oscillations of the cuneus in the α2 bands increased, and of the angular gyrus in the α and β1 bands decreased in TSD.
CONCLUSIONS: TSD impairs the alertness function among individuals. Increased effective connectivity from the cuneus to the middle frontal gyrus may represent overloads on the alertness network, resulting in participants strengthening top-down control of the attention system. Moreover, enhanced effective connectivity from the angular gyrus to the insula may indicate a special perception strategy in which individuals focus on salient and crucial environmental information while ignoring inessential stimuli to reduce the heavy burden on the alertness network.
CLINICAL TRIAL REGISTRATION: No: ChiCTR2400088448. Registered 19 August 2024, https://www.chictr.org.cn.
Bisoprolol fumarate/H6.25 mg is well tolerated in most patients. Most adverse effects (AEs) have been mild and transient. In more than 65,000 patients treated worldwide with bisoprolol fumarate, occurrences of bronchospasm have been rare. Discontinuation rates for AEs were similar for bisoprolol fumarate/H6.25 mg and placebo-treated patients.

In the United States, 252 patients received bisoprolol fumarate (2.5 mg, 5 mg, 10 mg or 40 mg)/H6.25 mg and 144 patients received placebo in two controlled trials. In Study 1, bisoprolol fumarate 5 mg/H6.25 mg was administered for 4 weeks. In Study 2, bisoprolol fumarate 2.5 mg, 10 mg or 40 mg/H6.25 mg was administered for 12 weeks. All adverse experiences, whether drug related or not, and drug related adverse experiences in patients treated with bisoprolol fumarate 2.5 mg to 10 mg/H6.25 mg, reported during comparable, 4 week treatment periods by at least 2% of bisoprolol fumarate/H6.25 mg-treated patients (plus additional selected adverse experiences) are presented in the following table:

Other adverse experiences that have been reported with the individual components are listed below.
A system is provided for automated monitoring the health of a patient. The system is unifying the approach of multi-sensing, robotic platform and cloud computing to monitor the health of the patient with zero or very minimal human intervention. The plurality of physiological parameters and the pathological values is sensed using the plurality of physiological sensors and the plurality of pathological sensors or using a smart phone of the patient. The body of the patient is scanned using a robotic arm. The data sensed by the sensor is then identifies a set of anomalies and send the set of anomalies to cloud server. A cognitive engine present on the cloud server is then diagnoses a disease using cloud computing and send the report to caregiver and doctor. According to another embodiment, a method is also provided for automated monitoring the health of the person using the above mentioned system.
The present invention relates to a wheelchair with a vital sign management function. The wheelchair with a vital sign management function enables a user to check a vital sign in real time even while the user uses the wheelchair. Moreover, the wheelchair with a vital sign management function generates a warning signal on an emergency and calls a nurse to save a valuable life. The wheelchair with a vital sign management function includes: a vital sign measuring unit installed in an armrest frame of the wheelchair and measuring the vital sign of the user in real time; and a vital sign responding unit storing vital sign information measured by the vital sign measuring unit and determining whether there is the emergency by analyzing the stored vital sign information. The vital sign responding unit automatically generates a warning signal when it is determined that there is an emergency, and calls a nurse by transmitting emergency information to a management terminal. The vital sign responding unit transmits the stored vital sign information to the management terminal in real time or periodically.
INTRODUCTION: Patients with chronic obstructive pulmonary disease (COPD) and emphysema experience malnutrition and pulmonary cachexia. Endoscopic lung volume reduction (ELVR) with endobronchial valves has not only improved lung function, exercise capacity, and quality of life but also influenced body weight. Only a few data are available on body composition changes after ELVR.
METHODS: This single-center prospective study of patients with advanced COPD investigates body composition before and after endoscopic valve treatment using multifrequency bioelectrical impedance analysis (BIA). The following parameters were evaluated in addition to clinical data and routine tests: body weight, body mass index (BMI), basal metabolic rate, total body water, body fat, cell percentage, phase angle, intracellular water (ICW), extracellular water (ECW), extracellular mass (ECM), body cell mass (BCM), lean body mass (ECM + BCM), and fat-free mass index.
RESULTS: A total of 23 patients (mean emphysema index 37.2 ± 7.5%, BMI 23.4 ± 4.3 kg/m2) experienced improvements in lung function and exercise capacity with ELVR. Complete lobar atelectasis was achieved in 39.1% of participants. A non-statistically significant increase in body weight and BMI was observed after ELVR (p = 0.111 and p = 0.102). BIA measurement revealed a worsening of phase angle, cell percentage and ECM/BCM and thus of body composition, but without statistical significance. This is mainly due to a statistically significant increase in ECM, ECW, and ICW (all p < 0.001).
CONCLUSION: ELVR demonstrated no beneficial changes in body composition, although patients tend to gain weight. A larger cohort is warranted to confirm these findings.
Shoulder: The superior labrum (fibrous cartilage) and biceps anchor improve joint stability by acting like a secondary stabilizer to the shoulder. Labral injuries are usually associated with anterior shoulder dislocation. When conservative treatment fails, such as physical therapy, strengthening programs, anti-inflammatories and activity modification to improve symptoms, surgical intervention may be required. Surgical treatments can include simple debridement (the medical removal of dead damaged or infected tissue), stabilization of the biceps-labrum complex through repair, or biceps tenodesis where the end of a tendon is joined surgically to the bone. Outcomes of SLAP (superior labral tear from anterior to posterior) repairs have been reported good throughout the literature, with reported success rates ranging from 71-97%.

Hip: The labrum of the hip is a fibrocartilaginous tissue that connects to the bone edge of the acetabulum (the socket of the hip bone), and deepens the acetabular socket while extending coverage of the femoral head; it also aids in hip stabilization. The goal of surgical intervention is to restore normal hip mechanics and treat existing damage. In an epidemiology study published in 2017, labral pathology was the most common diagnosis at 82% of the population. Of the 1,124 tears reported, 75.3% were repaired, 13.7% were reconstructed and 7.2% were debrided.
<P>PROBLEM TO BE SOLVED: To find out new functions of Puerariae Flos, to thereby increase the range of uses of the Puerariae Flos and to provide a new anti-diabetic agent.  <P>SOLUTION: The anti-diabetic agent is composed of a treated material of the Puerariae Flos. The treated material of the Puerariae Flos has excellent inhibitory actions on elevation of blood glucose level and has further inhibitory actions on glucide absorption by inhibitory actions on α-glucosidase. Since the treated material of the Puerariae Flos exhibits excellent anti-diabetic effects by the actions, the treated material can be utilized as a prophylactic or a therapeutic agent for the diabetes. Furthermore, prophylactic effects on various symptoms caused by obesity with accumulation of glucides can be expected.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Chronic Kidney Disease (CKD) is considered as a major public health problem as it can lead to end-stage kidney failure, which requires replacement therapy. A prompt and accurate diagnosis, along with the appropriate treatment, can delay CKD's progression End-stage renal disease (ESRD) is associated with significant alterations in cardiovascular function; homeostasis of body fluid, electrolytes, and acid-base equilibrium; bone metabolism, erythropoiesis; and blood coagulation. The prevalence of ESRD is increasing rapidly worldwide, as is the number of patients requiring surgery under general anesthesia. Patients with ESRD have significantly higher risks of perioperative morbidity and mortality due to multiple comorbidities Trimethylamine N-oxide (TMAO) is a gut microbiota metabolite derived from trimethylamine containing nutrient precursors such as choline, L-carnitine, and betaine. An increasing number of clinical studies have demonstrated a strong relationship between elevated plasma TMAO levels and adverse cardiovascular events. It is commonly agreed that TMAO acts as both an independent risk factor and a prognostic index for patients with cardiovascular disease , TMAO is considered as a potential biomarker and/or therapeutic target for diagnosis and treatment of patients with cardiovascular disease Probiotic work as antagonist for those strains which are responsible for the synthesis of TMAO precursor molecules in the gut and modulate miRNAs associated with the genes which are responsible for TMA lyases and ultimately play a role in conversion of diet precursor into TMA Control group: 40 patients will receive their standard therapy only. Intervention group (probiotic group): 40 patients will receive probiotic 5 billion unit per day with their standard therapy for 3 months
Patients from 12 to 35 years old with type I diabetes mellitus proved by anti-pancreatic beta cell antibodies and recently diagnosed (less than 6 weeks) will be included in this study. Peripheral blood hematopoietic stem cells will be mobilized from bone marrow of the patient with cyclophosphamide plus G-CSF (granulocyte-colony stimulating factor), collected by leukapheresis and cryopreserved. After 2-3 weeks, high dose immunosuppression is given (cyclophosphamide 200 mg/kg plus rabbit antithymocyte globulin 4.5 mg/kg) and stem cells are thawed and injected intravenously. This procedure is performed in isolated rooms at the Bone Marrow Transplantation Unit of the School of Medicine of Ribeirão Preto, University of São Paulo, Brazil. Patients are discharged from the hospital after engraftment and closely followed up to 2 months after transplantation (with at least weekly outpatient visits) and continue the followup for 5 years after transplantation. Clinical, hematological, metabolical and immunological evaluations are performed to analyse the effect of the transplant in the disease and in the hematopoetic and immunologic systems of the body. Patients fitting the inclusion criteria but not agreeing to perform the transplantation are the control group and they will be followed in parallel with transplanted patients.
Only patients scheduled for a whole body PET scan will be eligible. Subjects of all ages will be imaged after 4 h. The CT image from the routine scan will be used for the 2nd scan to avoid additional CT exposure. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
Participants enrolled in Phase 1, the dose level of cladribine, cytarabine, decitabine, and sorafenib will depend on when you join this study. Up to 2 dose levels of this drug combination may be tested. Between 3-6 participants will be enrolled in each dose level. The first group of participants will receive the starting dose level of this drug combination. If no intolerable side effects are seen, the next group of participants will receive the higher dose level of this drug combination.
Participants will receive injections of 1% triamcinolone into at least 1 and up to 3 facial inflammatory acne lesions. Participants will return to clinic at 24, 48, 72 hours, 7 days, and 14 days following injection for follow up assessment and photography.
This is a sequential study consisting of a screening period lasting up to 28 days, a 28 day (1 cycle) treatment period (T1) in a fed state, a 7 day washout period, a further 1 cycle treatment period (T2) in a fasted state and an extension to T2 until results from the primary analysis are available. During Treatment Period 1 and 2 all participants will receive selumetinib (25 mg/m2 bid). If a third treatment period (T3) is required, participants will enter a 7 day washout period followed by a treatment period in a fed state at an adjusted dose for 3 cycles.
PURPOSE OF REVIEW: This review explores the cardiovascular toxicity associated with cancer therapies, emphasizing the significance of the growing field of cardio-oncology. It aims to elucidate the mechanisms of cardiotoxicity due to radiotherapy, chemotherapy, and targeted therapies, and to discuss the advancements in human induced pluripotent stem cell technology (hiPSC) for predictive disease modeling.
RECENT FINDINGS: Recent studies have identified several chemotherapeutic agents, including anthracyclines and kinase inhibitors, that significantly increase cardiovascular risks. Advances in hiPSC technology have enabled the differentiation of these cells into cardiovascular lineages, facilitating more accurate modeling of drug-induced cardiotoxicity. Moreover, integrating hiPSCs into clinical trials holds promise for personalized cardiotoxicity assessments, potentially enhancing patient-specific therapeutic strategies. Cardio-oncology bridges oncology and cardiology to mitigate the cardiovascular side-effects of cancer treatments. Despite advancements in predictive models using hiPSCs, challenges persist in accurately replicating adult heart tissue and ensuring reproducibility. Ongoing research is essential for developing personalized therapies that balance effective cancer treatment with minimal cardiovascular harm.
OBJECTIVE: Sleep varies between individuals in response to sleep-wake history and various environmental factors, including light and noise. Here we report on the intranight variation of the ultradian nonrapid eye movement-rapid eye movement (NREM-REM) sleep cycle in 369 participants who have contributed to different laboratory studies from 1994 to 2020 at the Centre for Chronobiology, Basel, Switzerland.
RESULTS: We observed a large interindividual variability in sleep cycle duration, including NREM and REM sleep episodes in healthy participants who were given an 8-hour sleep opportunity at habitual bedtime in controlled laboratory settings. The median sleep cycle duration was 96 minutes out of 6064 polysomnographically-recorded cycles. The number and duration of cycles were not normally distributed, and the distribution became narrower for NREM sleep and wider for REM sleep later in the night. The first cycle was consistently shorter than subsequent cycles, and moderate presleep light or nocturnal noise exposure had no significant effects on ultradian sleep cycle duration. Age and sex significantly affected NREM and REM sleep duration, with older individuals having longer NREM and shorter REM sleep particularly in the end of the night, and females having longer NREM sleep episodes. High sleep pressure (ie, sleep deprivation) and low sleep pressure (ie, multiple naps) altered ultradian sleep cycles, with high sleep pressure leading to longer NREM sleep in the first cycle, and low sleep pressure leading to longer REM sleep episodes. Positive correlations were observed between N2 and NREM duration, and between N1 and REM duration. Weak intrasleep REM sleep homeostasis was also evident in our data set.
CONCLUSIONS: We conclude that ultradian sleep cycles are endogenous biological rhythms modulated by age, sex, and sleep homeostasis, but not directly responsive to (moderate levels of) environmental cues in healthy good sleepers.
The utility model provides a female sterilization film, which relates to the improvement of dosage form which is used for a female genitalia inflammation medicine film. To solve the problems that when the existing medicine with various dosage forms, the time of loss and the time of action are short, operation is complicated, carrying is not convenient, etc. the medicine is made of water-soluble medicine resin, male nonionic surfactant, etc. which are scientifically compatible. The utility model can slowly dissolves under the action of humor in the vagina, can lead active components of sterilization to slowly release to reach each focus of a human body, and can effectively play the role of sterilizing various gynecology germs. The utility model has the advantages of economy and convenience.
Simvastatin: Co-administration of simvastatin with amlodipine increases the systemic exposure of simvastatin. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily. [see Clinical Pharmacology (12.3)]. 

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended and adjust the dose when appropriate [see Clinical Pharmacology (12.3)]. 

CYP3A Inhibitors: Co-administration of amlodipine with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is co-administered with CYP3A inhibitors to determine the need for dose adjustment. 

CYP3A Inducers: No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers.
This is an open-label non-randomized safety study to provide early access to TMC114 for HIV-1 infected patients who have failed and exhausted regimens based on commercially available antiretroviral (ARV) therapy and who are ineligible for participation in any other Tibotec-sponsored trial. The safety and tolerability of TMC114 in combination with low dose ritonavir (RTV) and other ARVs in highly ARV-experienced HIV-1 infected patients with limited or no treatment options will be assessed. Treatment will be continued until treatment-limiting toxicity, lost to follow-up, withdrawal, pregnancy, discontinuation of TMC114 development or when TMC114 is commercially available to the patient. Total daily dose is 600 mg TMC114 twice daily, each intake in combination with one capsule of 100 mg Ritonavir. Since TMC114 is formulated as 300mg tablets (F014) this means 2X2 tablets per day, taken orally. Treatment will be continued until treatment-limiting toxicity, lost to follow-up, withdrawal, pregnancy, discontinuation of TMC114 development or when TMC114 is commercially available to the patient.
Ciprofloxacin ophthalmic solution is a synthetic, sterile, multiple dose, antimicrobial for topical ophthalmic use. Ciprofloxacin is a fluoroquinolone antibacterial active against a broad spectrum of gram-positive and gram-negative ocular pathogens. It is available as the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1- piperazinyl)-3-quinoline-carboxylic acid. It is a faint to light yellow crystalline powder with a molecular weight of 385.8. Its empirical formula is C17H18FN3O3∙HCl∙H2O and its chemical structure is as follows:

Ciprofloxacin differs from other quinolones in that it has a fluorine atom at the 6-position, a piperazine moiety at the 7-position, and a cyclopropyl ring at the 1-position.

Each mL of ciprofloxacin ophthalmic solution contains: Active: ciprofloxacin HCl 3.5 mg equivalent to 3 mg base. Preservative: benzalkonium chloride 0.006%. Inactives: sodium acetate, acetic acid, mannitol 4.6%, edetate disodium 0.05%, hydrochloric acid and/or sodium hydroxide (to adjust pH) and purified water. The pH is approximately 4.5 and the osmolality is approximately 300 mOsm.